Durvalumab plus anlotinib versus durvalumab alone as maintenance treatment in extensive-stage small-cell lung cancer (DURABLE): a multicenter, randomized, phase II trial and biomarker analysis
Hua Zhong
Nature Communications, Published online: 25 May 2026; doi:10.1038/s41467-026-73562-7 While first-line immunochemotherapy has shown efficacy in patients with extensive-stage small-cell lung cancer (ES-SCLC), survival benefit is limited. Here, the authors report a phase II randomised clinical trial comparing durvalumab (anti-PD-1) plus anlotinib (multi-TKI) against durvalumab alone as maintenance therapy in patients with ES-SCLC along with biomarker analysis.